Here's some of what is coming soon to NeurologyLive® this week.
|Articles|August 1, 2019
Happy Anniversary, NeurologyLive!
Author(s)NeurologyLive® Staff
On our anniversary, take a look back at some of our most popular articles and interviews across a range of neurology topics.
Advertisement
Celebrate NeurologyLive's anniversary with a look back at our most popular coverage over the last year. From breaking news and in-depth topical reviews, to engaging interviews straight from the conference floor, NeurologyLive is proud to provide our readers with the most up-to-date and clinically relevant content to help improve clinical decision-making.
Click through the links below to review top content you may have missed:
If you have any comments or suggestions, or if you are interested in contributing to NeurologyLive, please reach out to Alicia Bigica at abigica@neurologylive.com.
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP
3
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
4
Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab
5